James Gordon
Stock Analyst at JP Morgan
(2.95)
# 1,586
Out of 5,050 analysts
10
Total ratings
100%
Success rate
30.18%
Average return
Main Sectors:
Top Industries:
Stocks Rated by James Gordon
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARGX argenx SE | Maintains: Overweight | $830 → $925 | $848.03 | +9.08% | 7 | Nov 7, 2025 | |
| GRFS Grifols | Maintains: Neutral | $7.6 → $10 | $8.31 | +23.95% | 1 | Jun 17, 2025 | |
| GMAB Genmab | Downgrades: Neutral | n/a | $28.80 | - | 1 | Aug 20, 2024 | |
| FGEN FibroGen | Upgrades: Neutral | n/a | $11.36 | - | 1 | Apr 7, 2021 |
argenx SE
Nov 7, 2025
Maintains: Overweight
Price Target: $830 → $925
Current: $848.03
Upside: +9.08%
Grifols
Jun 17, 2025
Maintains: Neutral
Price Target: $7.6 → $10
Current: $8.31
Upside: +23.95%
Genmab
Aug 20, 2024
Downgrades: Neutral
Price Target: n/a
Current: $28.80
Upside: -
FibroGen
Apr 7, 2021
Upgrades: Neutral
Price Target: n/a
Current: $11.36
Upside: -